Cytokines in predicting JAK inhibitors clinical efficacy for COVID-19
- 7 November 2023
- journal article
- research article
- Published by Alfmed LLC in Medical alphabet
- No. 23,p. 7-10
Abstract
Janus kinases inhibitors (JAKi) have an immunosuppressive effect due to the normalization of levels of proinflammatory cytokines, are used in the treatment of cytokine storm in COVID-19. This fact makes it necessary to search a predictor of an efficacy of this small-molecules. The aim of the study. To evaluate the possibility of using cytokines in predicting the efficacy of JAKi in COVID-19. Materials and methods. We examined 86 patients with COVID-19: 50 men and 36 women. The age was 57,0; (50,0–65,0) years. The SARS-CoV-2 presence was confirmed by PCR. The control group consisted of 30 healthy donors matched by sex and age. The criterion for the efficacy of JAKi was recovery, in efficacy – switching to another drug, or death. The serum concentration of IL-1β, –6, –8, –17, TNF-α and GM–CSF by ELISA was estimates using Invitrogen test-systems (USA), according to the manufacturer’s instructions. Results. In COVID-19 patients who received baricitinib (BTC), compared with healthy individuals, basal (before JAKi starting) IL-6, TNF-α serum concentrations were increased; tofacitinib (TFT) – IL-6, ruxilitinib (RLT) – IL-6 and TNF-α. A decrease of IL-1β and GM–CSF serum concentration was noted before the start of TFT and RLT. Basal concentrations of IL-6 and TNF-α are most statistically strongly associated with the diagnosis COVID-19. After 5 days of treatment with BTC, there was an increase in IL-8 level compared to the basal, a decrease in the GM–CSF concentration and a slight increase IL-6 concentration relative to healthy donors (p < 0.05 in all cases). Basal concentration of IL-17 (more than 13.9 pg/ml) indicated the possibility of successful RLT treatment (area under the ROC-curve = 0.99; AP = 99 %; DS = 80 %; OP+ = 5.0; OP– = 0.2; CI: 0.9–1.0). Conclusions. Basal serum concentration of cytokines may predict JAKi efficacy in COVID-19 patients.Keywords
This publication has 13 references indexed in Scilit:
- Biomarkers in COVID-19: An Up-To-Date ReviewFrontiers in Pediatrics, 2021
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19New England Journal of Medicine, 2021
- JAK-STAT Pathway Inhibition and their Implications in COVID-19 TherapyPostgraduate Medicine, 2020
- Innate immunity in coronavirus infectionRussian Journal of Infection and Immunity, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Interleukin-6 (IL-6) and IL-17 Synergistically Promote Viral Persistence by Inhibiting Cellular Apoptosis and Cytotoxic T Cell FunctionJournal of Virology, 2014
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- JAK/STAT signaling by cytokine receptorsCurrent Opinion in Immunology, 1998